Today's Information

Provided by: PharmaEngine, Inc.
SEQ_NO 2 Date of announcement 2022/04/18 Time of announcement 11:46:26
Subject 
 Clarification of media reporting
Date of events 2022/04/18 To which item it meets paragraph 53
Statement 
1.Date of occurrence of the event:2022/04/18
2.Company name:PharmaEngine Inc.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Name of the reporting media:
  Column B4 of Commercial Times and Column B4 of Economic Daily News
  of 2022/04/16
6.Content of the report: (translated from Chinese)
  …ONIVYDE sales has outperformed in Asia region, investors highly
  expected that ONIVYDE sales in EU region might reach to USD$100-120M
  this year and hit the second milestones criteria, which could recognize
  around USD$40M; If everything goes to plan, PharmaEngine could earn
  a share capital…
  ...ONIVYDE in 2L SCLC global Phase III trial readout would be in 3Q22,
  get approval by next year as expected; ONIVYDE in 1L PDAC global
  Phase III trial readout would be in 1Q23, which could trigger another
  new indication milestone USD$35M…
7.Cause of occurrence:
  1. PharmaEngine has not disclosed publically any financial forecast,
     especially ONIVYED global sales projection. Furthermore, as our NDA
     with our global partner IPSEN, we should not disclose any milestone
     details.
  2. The update of new indication progress for ONIVYDE would be based
     on IPSEN's public information, Ex: 2L SCLC phase III trial data
     readout would be 2H22; 1L PDAC phase III trial data readout would be
     1H23. As for NDA timeline and milestone details should align with our
     global partners.
8.Countermeasures:Clarification of reporting content
9.Any other matters that need to be specified:The Company didn't provide
  any forecasts. Official announcements shall take precedence for actual
  financial numbers and operations at MOPS. Therefore, the investors will
  bear investment risk and should carefully consider investment decisions.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

PharmaEngine Inc. published this content on 18 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 April 2022 03:53:08 UTC.